SAN DIEGO, Aug. 8, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today announced that management will be presenting at two upcoming investor conferences. The details are as follows:
|Wedbush Life Sciences Management Access Conference|
|Hotel: Le Parker Meridien Hotel in New York City|
|Time: Wednesday, August 14, 2013 at 8:00 a.m. Eastern|
|Canaccord Genuity Growth Conference|
|Hotel: Intercontinental in Boston|
|Time: Thursday, August 15, 2013 at 10:00 a.m. Eastern|
To listen to a live webcast or a replay of either presentation, please visit the Investor Relations section of the Company's website at www.receptos.com. A replay will be available for 7 days after the event.
Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. The Company's lead program, RPC1063, is a sphingosine 1-phosphate 1 receptor (S1P1R) small molecule modulator candidate for immune indications, including relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). The Company is also developing RPC4046, an anti-interleukin-13 (IL-13) antibody for an allergic/immune-mediated orphan disease, eosinophilic esophagitis (EoE). Receptos has established expertise in high resolution protein crystal structure determination, biology and drug discovery for G-protein-coupled receptors (GPCRs).
CONTACT: Media and Investor Contact: Graham K. Cooper Chief Financial Officer, Receptos (858) 652-5708 firstname.lastname@example.org